Forum Topics PME PME Valuation and Market

Pinned straw:

Added 2 months ago

During this week's Strawman Meeting, we discussed valuations and taking a long term view as an edge in long term investing.

And, lo and behold, once again I am confronted with the worst investing decision in my life - that of doing some "analysis" on $PME in mid-2023 and concluding that at $70, it was too expensive.

And so, today it announces another monster contract ($300m for 10 years) and to stop myself feeling terrible, I've done a quick update. By the way, on that news the SP jumps $2bn! (As an analyst, when I'm feeling glum I do some analysis - it makes me feel better!)

So the structure of this analysis is as follows:

1) Quick DCF

2) Quick market analysis

3) Conclusion and discussion


1) Quick DCF

So, having looked at the accounts over the last 3-4 years, i've decided to run out a DCF for 20 years. It's pretty easy to model.

First 10 years, revenue CAGR 27%; Opex CAGR 20%

Next 10 years, revenue CAGR 15%; Opex CAGR 10%

Common assumptions:

  • Ongoing capex at 5% of revenue (assuming they both update and extend the platform to take over more and more of the total available market of medical imaging software)
  • Depreciate 34% of relevant LT assets pa (PPE, Intangibles, Leases)
  • SOI growth at 0.15% p.a.
  • Tax: 30%
  • Cashflow growth beyond the explicit period 5% (note: you usually don't run more than 4%)
  • WACC = 9%
  • 100% equity funding (no debt) + a sensitivity with LT Debt:EBITDA = 0.5


Valuation $200/share

Of course, you can bump this up a bit if you add a little gearing to the balance sheet. If I add 50% of EBITDA as long term debt, I then get:

Valuation $218/share

As ever, you can get all sorts of valuations by tweaking the parameters, and I have omitted a few things (like deferred taxes etc. and adjusting the WACC in the leverage case). Playing with this model, I can get valuations down as low as $160 and up north of $230,but that's not the point of this thread. That comes next.


2) The Market

I'm reasonably confident that the global market for medical imaging software can be estimated to be in the ball park of A$5.6bn (fairly wide range of sources around this, but it's in the ball park).

Now $PME is not playing in this total market, but for the sake of this analysis (just like with $WTC), let's assume that over time it expands from its current focus to dominate the wider market.

So, today its market share is only 7%. Lot's of running room.

We know this market is growing at 7-8% per annum, and if I assume that for the next decade it grows at 8% pa, and thereafter at a more modest but still healthy 5%pa, then in 2045 the global market has become $18bn.

In 2045, with my DCF assumptions, $PME's market share has become 46%.

Now that would be a truly dominant market share when you look at how fragmented the market is today and some of the big names playing. (GE Healthcare, Siemens, Agfa-Gevaert, Hologic, Pie Medical, AQUILAB, MIM Software, Merge Healtcare, ScienceSoft, Acuo Tech. to name the big players) Most a equipment makers who develop their own software to use witht he equipment, with overlapping functionality for $PME. So that's a big source of $PME's competitive advantage, as its machine-maker agnostic.

Just to be clear, my market size analysis is for SOFTWARE only. Not the hardware. The global hardware market is worth north of A$70bn.


3) My Conclusion

These are just quick, rough calculations you can do in a few minutes. They're broadbrush. They are almost certainly wrong.

BUT, I just have to believe too much to have a conviction that $PME represents a good investment at $228, let alone $248,

There are too many other established players investing to compete for me to believe that $PME will eventually own some 50% of the total addressible market. It's a long bow to draw. Of course, if you are prepared to believe that, then equally, the analysis shows the valuations are justified for the long term. Afterall, maybe they do become the Windows of Medical Imaging! In software, there are precendents, e.g., Google for search.

I would consider investing today in $PME around $120-$150. I'd have to do a deeper dive to find my entry point, but that's a ballpark based on what I've done in 30 minutes. (My CommSec alert is at $170 ... don't think it will triggered any time soon.)

I don't believe today's news of a $300m, 10-year contract warrants a SP movement of +$2bn. These are the kinds of deals $PME MUST bring in, if it is to justify any valuation north of $150. Of course, the SP move could be rational if the market is efficienctly assessing this deal as increasing the chances of success that $PME is going to eventually dominate this market.

So, there you go. Let's see how well this post ages. And above all, do your own research!

Well done to all you have invested in $PME - my hat off to you, and this post shows how analysis can get in the way of being a great investor. But I am going to stick to my process - it serves me well more often than it lets me down.


Reflection

As a personal anecdote, a friend of a StrawPerson at last week's Brisbane drinks had just bought their first ASX shares. $PME at the recommendation of a friend at (I recall) about $217. As I drove home in my Uber after the drinks, I wondered what the conversation would be in a year's time. It didn't cross my mind they'd be up 14% in one week!

Disc: Not held, never have. ;-(

Solvetheriddle
Added a month ago

@mikebrisy , the list of missed opportunities is large for all of us. Beware the resulting bias. Just because something has been rewarded in the market does not mean that it was completely forecastable or was a reasonable base case.

re PME i undertake a similar process to you, the numbers are a bit different. you can play around with penetration and industry growth rates etc. in broad terms i get a complete US market conquest 99% market share valuing the stock at $142 SP, a complete ROW (est) conquest of another $113, and then adjacencies on top of that--add what you want (but probably less then the others given the time lag). so it is "doable", would i actually back that happening? not me, no margin for error there at all. so for me its a lets see what happens

as i have said for a while since the SP has already gone way beyond total US market dominance, i am amused when the SP responds incredibly enthusiastically to a ct win. the new contracts need to be outside the US, even then that is already implied in the SP, imo, the new cts need to be in completely new areas, as i say, the Martian market is as yet uncontested! FOMO at play?

Great business but a huge SP, there are more alternatives in the market.

That's my view could be wrong

32

mikebrisy
Added a month ago

@Solvetheriddle agree totally.

Ultimately, my approach to valuation is “if I never sell, what is the value of the cash I expect to receive over the long run.” And what do I have to believe in terms of revenues, margins, capex, market, competition etc. That’s my North Star. I fully recognise that other investors purchase shares on a different basis altogether. For many, it appears, that just having the SP going from bottom left to top right is enough. But that has a zero connection to my basis for investing. I’m not saying they won’t make money. Just that that”s not me.

And therefore many investors will be willing to pay up a lot more than me, sometimes, or even often.

Your point on $PME about US contracts moving the SP is spot on. That can’t be right (fundamentally) unless they indicate the US is becoming significantly bigger than is assumed. Which as far as I know, it isn’t. The valuation assumes global market dominance. So we need to see big contracts ex-US.

So, on fundamentals, I think, the valuation assumes $PME likely has to evolve beyond imaging at some stage. But I have no reason to put that in my base case or upside case. It would be an artefact to make my valuation justify the SP. I try not to do that.

So, if you are “bottom left to top right” investor, $PME is a “BUY”. But it you are valuing the cash stream you expect to receive by holding it forever, I think it is a “SELL”.

There are many other opportunities on the ASX. So I’ll happily just keep looking for the ones where I believe the SP is less than I am confident the company is worth.

I was watching a recent interview with Howard Marks, where he said the best way to achieve horrible returns over the long term in investing in equities, is to buy businesses when they are overvalued because everyone is hyped about them. Even quality firms.

28

edgescape
Added a month ago

I'll just say the power of passive funds is too strong and sometimes not worth wasting time thinking about valuation when they have already jumped in earlier than you can say "buy"

15

mikebrisy
Added a month ago

@edgescape that may be true, but as a long term investor, I also know that tides change direction over time when your time horizon is many years.

I think it is also fair to say that the higher the tide runs in the flood, the harder it runs on the ebb.

When I buy a stock I am prepared (usually) to hold it forever, so that I will at minimum receive the free cash flows the business generates. That way, it doesn't matter to me which way the tide is flowing.

Of course, the tide influences my psychology and also my conviction. It is easy to believe your analysis when you are flowing with the tide. It harder when you are against it. After all, can I really believe that I am right and everyone else is wrong?

24

edgescape
Added a month ago

@mikebrisy

As someone once told me, don't lecture stupid people.

And passive funds are analogous to stupid people

There are better opportunities than PME, WES ... and even the ASX as a whole and that much I can agree.

18
thunderhead
Added 2 months ago

It's just an astounding long-term wealth creation machine, so all I can do is doff my hat to long-term holders.

I must lay claim to the dunce hat @mikebrisy, as I have been watching PME right from the single digits without ever committing any capital to it over many years!

23
Karmast
Added 2 months ago

Don't feel too bad @mikebrisy. I too have missed the PME bullet train on the basis of it being too expensive when it was under $100 a share. So, very wrong so far!

My valuation process is over 5 years, so a lot shorter than yours. Even if they can keep growing earnings at 20% p.a. and be on a PE of 100, I can't pay more than $125 to get a market matching return.

Great company and maybe a great buy if we have another covid type flash crash but it's too risky for me at the current multiple which is 20 times the market.

If enough investors are willing to keep paying up though, who knows how long it can go on for...

24

Slomo
Added 2 months ago

From here PME probably needs to become the de facto industry standard to justify its current valuation, which I think it has a chance of being.

Just 7 % of a growing market and lots of adjacencies to plunder.

Bear Points

Sentiment (like the force) is strong in this one so everyone who wants to own it probably does now and it's hard to see where the marginal buyers will come from beyond the index algos and some year end window dressing.

They have fat margins that will be a magnet for competitors and I don't think the network effects are strong enough to make this a winner takes all market. On the flip side they are years ahead of their competition and Sam thinks this gap is widening.

They have also probably had most of the margin expansion they're likely to see so share price rises are dependent on faster or longer duration growth and multiple expansion, hard to see much more of the latter but I've thought that for a while.

PME has effectively had their part of the market to themselves - hence the high growth at high margins, but if this were to change, that multiple could drop a long way.

I've been trimming from $200 so now down to a much smaller position - every decision to sell this along the way has been a mistake - with the benefit of hindsight...

Disc: Held (residual position)

27

thunderhead
Added 2 months ago

One point in favour of additional marginal buyers is interest from overseas. That is a wide and deep pool of capital, and the company is still largely undiscovered by overseas fundies with a global mandate, though they are going to be paying a very steep price for a piece of it of course.

18

edgescape
Added 2 months ago

Everyone talks about PME being expensive

But what about Dropsuite which happens to be the most popular in Strawman?

Everyone complains about PME being expensive and then many here go and buy DSE which has a similar PE.

What's the thesis behind buying DSE over PME?

28b8cc44a9351a16b60937157c4762b7dd267f.png

I think I'll choose PME over DSE any day :)

17

Strawman
Added 2 months ago

On a PE basis you're right @edgescape, but I'd argue DSE is investing heavily in growth initiatives, which is suppressing current earnings. So it's net margins are very low, but promedicus, which is a more mature company has much higher net margins (~50%!, and probably not far from where they will stabilise at). DSE is at 2.8% net margins currently, but that *should* improve as they achieve some operating leverage.

Another way to look at it is by comparing price to sales. DSE is about 5.5x, PME is ~130x. And PME is a MUCH bigger company.

So neither is cheap by traditional measures, but there's a bit of nuance here.

(Also DSE is ranked #25, not #1. Make sure you have 'premium only toggle set to on on the company page)

That's my take anyway, let us know if I've missed something.

29

edgescape
Added 2 months ago

@Strawman

Thanks for clarifying

I didn't say that DSE is the top stock but it feels like it is the more popular stock than others as it gets the most activity here with all the meetings and discussions.

With DSE there is also the question of product transparency and whether or not research spending will pay off and become a key differentiator against other players. Microsoft for instance will always do whatever it takes as well and most if not all cloud players have the infrastructure and know how to create resilience in their service.

It was also a bad decision for me agreeing on the sell call here at 40 dollars when I should have bought.

11

Strawman
Added 2 months ago

Absolutely @edgescape. Their multiple is only justified if they can materially accelerate profit growth.

Although, I guess my point is that that is equally (if not more) true for PME.

Still, I do think PME is by far the superior business.

16

edgescape
Added a month ago

Well said.

Best explanation I've heard in a while and couldn't agree more.

fd7525fec2537882065b1e5487652b200a6727.png

21

actionman
Added a month ago

@edgescape good observation. I know Hyperion hold a large percentage of PME and if they trim their position size the share price could drift lower.

I see PME down 9% on no news today. It’s a wild ride for a market cap of that size.

10

thunderhead
Added a month ago

PME wasn't the only growth darling selling off today, though it sold off in a more outsized manner probably because of its more egregious valuation. Typical profit-taking/rotation I think, though who knows how long it will go on for?

14